Format
Sort by
Items per page

Send to

Choose Destination

See also: BRD3 bromodomain containing 3 in the Gene database

brd3 in Homo sapiensMus musculusRattus norvegicusAll 232 Gene records

Search results

Items: 1 to 20 of 154

1.

BET bromodomain inhibitors: fragment-based in silico design using multi-target QSAR models.

Speck-Planche A, Scotti MT.

Mol Divers. 2018 Nov 12. doi: 10.1007/s11030-018-9890-8. [Epub ahead of print]

PMID:
30421269
2.

NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.

French CA.

Pathol Int. 2018 Nov;68(11):583-595. doi: 10.1111/pin.12727. Epub 2018 Oct 26. Review.

PMID:
30362654
3.

Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.

Rudman MD, Choi JS, Lee HE, Tan SK, Ayad NG, Lee JK.

Exp Neurol. 2018 Nov;309:181-192. doi: 10.1016/j.expneurol.2018.08.005. Epub 2018 Aug 19.

PMID:
30134146
4.

RNAs interact with BRD4 to promote enhanced chromatin engagement and transcription activation.

Rahnamoun H, Lee J, Sun Z, Lu H, Ramsey KM, Komives EA, Lauberth SM.

Nat Struct Mol Biol. 2018 Aug;25(8):687-697. doi: 10.1038/s41594-018-0102-0. Epub 2018 Aug 3.

PMID:
30076409
5.

Binding Assays for Bromodomain Proteins: Their Utility in Drug Discovery in Oncology and Inflammatory Disease.

Zolotarjova NI, Wynn R.

Curr Protoc Pharmacol. 2018 Mar;80(1):3.16.1-3.16.14. doi: 10.1002/cpph.35.

PMID:
30040205
6.

Molecular analysis of an asbestos-exposed Belgian family with a high prevalence of mesothelioma.

Hylebos M, Op de Beeck K, van den Ende J, Pauwels P, Lammens M, van Meerbeeck JP, Van Camp G.

Fam Cancer. 2018 Oct;17(4):569-576. doi: 10.1007/s10689-018-0095-1.

PMID:
29961174
7.

Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.

Xu L, Chen Y, Mayakonda A, Koh L, Chong YK, Buckley DL, Sandanaraj E, Lim SW, Lin RY, Ke XY, Huang ML, Chen J, Sun W, Wang LZ, Goh BC, Dinh HQ, Kappei D, Winter GE, Ding LW, Ang BT, Berman BP, Bradner JE, Tang C, Koeffler HP.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5086-E5095. doi: 10.1073/pnas.1712363115. Epub 2018 May 15.

PMID:
29764999
8.

Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition.

Runcie AC, Zengerle M, Chan KH, Testa A, van Beurden L, Baud MGJ, Epemolu O, Ellis LCJ, Read KD, Coulthard V, Brien A, Ciulli A.

Chem Sci. 2018 Jan 24;9(9):2452-2468. doi: 10.1039/c7sc02536j. eCollection 2018 Mar 7.

9.

CIC-NUTM1 fusion: A case which expands the spectrum of NUT-rearranged epithelioid malignancies.

Schaefer IM, Dal Cin P, Landry LM, Fletcher CDM, Hanna GJ, French CA.

Genes Chromosomes Cancer. 2018 Sep;57(9):446-451. doi: 10.1002/gcc.3. Epub 2018 Aug 14.

PMID:
29700887
10.

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.

Law RP, Atkinson SJ, Bamborough P, Chung CW, Demont EH, Gordon LJ, Lindon M, Prinjha RK, Watson AJB, Hirst DJ.

J Med Chem. 2018 May 24;61(10):4317-4334. doi: 10.1021/acs.jmedchem.7b01666. Epub 2018 May 3.

PMID:
29656650
11.

Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability.

Cho J, Chang YH, Heo YJ, Kim S, Kim NK, Park JO, Kang WK, Lee J, Kim KM.

ESMO Open. 2018 Mar 15;3(3):e000326. doi: 10.1136/esmoopen-2018-000326. eCollection 2018.

12.

BET-ting on Nrf2: How Nrf2 Signaling can Influence the Therapeutic Activities of BET Protein Inhibitors.

Chatterjee N, Bohmann D.

Bioessays. 2018 May;40(5):e1800007. doi: 10.1002/bies.201800007. Epub 2018 Mar 30. Review.

PMID:
29603290
13.

The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators.

Wai DCC, Szyszka TN, Campbell AE, Kwong C, Wilkinson-White LE, Silva APG, Low JKK, Kwan AH, Gamsjaeger R, Chalmers JD, Patrick WM, Lu B, Vakoc CR, Blobel GA, Mackay JP.

J Biol Chem. 2018 May 11;293(19):7160-7175. doi: 10.1074/jbc.RA117.000678. Epub 2018 Mar 22.

PMID:
29567837
14.

Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).

Welti J, Sharp A, Yuan W, Dolling D, Nava Rodrigues D, Figueiredo I, Gil V, Neeb A, Clarke M, Seed G, Crespo M, Sumanasuriya S, Ning J, Knight E, Francis JC, Hughes A, Halsey WS, Paschalis A, Mani RS, Raj GV, Plymate SR, Carreira S, Boysen G, Chinnaiyan AM, Swain A, de Bono JS; International SU2C/PCF Prostate Cancer Dream Team.

Clin Cancer Res. 2018 Jul 1;24(13):3149-3162. doi: 10.1158/1078-0432.CCR-17-3571. Epub 2018 Mar 19.

PMID:
29555663
15.

miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein.

Tonouchi E, Gen Y, Muramatsu T, Hiramoto H, Tanimoto K, Inoue J, Inazawa J.

Sci Rep. 2018 Mar 14;8(1):4482. doi: 10.1038/s41598-018-22767-y. Erratum in: Sci Rep. 2018 Apr 25;8(1):6769.

16.

Lyar-Mediated Recruitment of Brd2 to the Chromatin Attenuates Nanog Downregulation Following Induction of Differentiation.

Luna-Peláez N, García-Domínguez M.

J Mol Biol. 2018 Apr 13;430(8):1084-1097. doi: 10.1016/j.jmb.2018.02.023. Epub 2018 Mar 2.

PMID:
29505757
17.

BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment.

Andrieu GP, Shafran JS, Deeney JT, Bharadwaj KR, Rangarajan A, Denis GV.

J Leukoc Biol. 2018 Aug;104(2):265-274. doi: 10.1002/JLB.5RI0917-380RR. Epub 2018 Mar 1. Review.

PMID:
29493812
18.

Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia.

DeMars KM, Yang C, Castro-Rivera CI, Candelario-Jalil E.

Biochem Biophys Res Commun. 2018 Feb 26;497(1):410-415. doi: 10.1016/j.bbrc.2018.02.096. Epub 2018 Feb 12.

PMID:
29448097
19.

BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.

Andrieu GP, Denis GV.

Mol Cancer Res. 2018 Apr;16(4):580-586. doi: 10.1158/1541-7786.MCR-17-0568. Epub 2018 Feb 7.

PMID:
29437854
20.

Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.

Giridhar P, Mallick S, Kashyap L, Rath GK.

Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821. doi: 10.1007/s00405-018-4882-y. Epub 2018 Jan 22. Review.

PMID:
29356890

Supplemental Content

Loading ...
Support Center